WhaleCreep

Avidity Partners Management LP 13F holdings, Q2 2022

Hedge fundSEC filingsCompare with another fundHoldings as of 2022-06-30, filed 2022-08-15

Avidity Partners Management LP disclosed 82 US equity positions worth $4.4bn in its Q2 2022 13F filing. Its largest position is AZN at 5.3% of the reported book, followed by VRTX and ARGX. Versus Q1 2022 it opened 10 new positions, added to 31, reduced 12 and exited 19.

$4.4bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
82
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
5.3%
Largest position
The largest single position as a share of the reported equity book.
45.0%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
32
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2022: 10 new, 31 added, 12 reduced, 19 exited

50 of 82
AZN ASTRAZENECA PLCHealthcare5.3%$231m3.50m−5.4%reduced
VRTX VERTEX PHARMACEUTICALS INCHealthcare5.1%$223m793,000+45%added
ARGX ARGENX SEHealthcare5.0%$217m572,500+225%added
ELV ELEVANCE HEALTH INCHealthcare4.9%$213m441,000+10%added
AVTR AVANTOR INCHealthcare4.7%$207m6.65m+17%added
LLY ELI LILLY & COHealthcare4.5%$198m610,000–new
HUM HUMANA INCHealthcare4.4%$193m412,300+107%added
UTHR UNITED THERAPEUTICS CORP DELHealthcare3.9%$171m725,600+0.9%added
JNJ JOHNSON & JOHNSONHealthcare3.7%$160m900,200+154%added
HORIZON THERAPEUTICS PUB L no ticker–3.4%$148m1.86m+64%added
NBIX NEUROCRINE BIOSCIENCES INCHealthcare3.3%$143m1.47m+27%added
ARVN ARVINAS INCHealthcare3.2%$141m3.36m+15%added
XBI SPDR SERIES TRUST–3.2%$139m1.88m+326%added
MCK MCKESSON CORPHealthcare2.9%$127m388,800+105%added
UNH UNITEDHEALTH GROUP INCHealthcare2.9%$124m242,200−6.7%reduced
ABBV ABBVIE INCHealthcare2.7%$116m755,000−49%reduced
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.4%$105m5.45m+13%added
CTLTEUR CATALENT INC–2.4%$102m955,000+22%added
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare2.3%$101m3.59m+13%added
SGENUSD SEAGEN INC–2.2%$97.3m550,000+450%added
BSX BOSTON SCIENTIFIC CORPHealthcare2.2%$94.1m2.52m+111%added
BIIB BIOGEN INCHealthcare2.1%$89.8m440,566+21%added
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare2.0%$88.3m1.48m+70%added
ACHC ACADIA HEALTHCARE COMPANY INHealthcare1.6%$70.0m1.03m–new
NTLA INTELLIA THERAPEUTICS INCHealthcare1.3%$58.2m1.13m+188%added
LEGN LEGEND BIOTECH CORPHealthcare1.3%$55.0m1.00m−8.7%reduced
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare1.2%$50.7m1.44m+51%added
IMCR IMMUNOCORE HLDGS PLCHealthcare1.2%$50.4m1.35m−1.0%reduced
NTRA NATERA INCHealthcare1.1%$48.5m1.37m+5.3%added
ITCIEUR INTRA-CELLULAR THERAPIES INC–1.0%$44.3m775,504–new
IDYA IDEAYA BIOSCIENCES INCHealthcare0.9%$41.0m2.97m+11%added
BLU BELLUS HEALTH INC NEW–0.9%$39.4m4.26m+16%added
ALT ALTIMMUNE INCHealthcare0.8%$34.9m2.98m+4.0%added
KEZAR LIFE SCIENCES INC no ticker–0.8%$33.5m4.05m+15%added
RNAGBP AVIDITY BIOSCIENCES INC–0.7%$30.2m2.08m+1.7%added
KRTX KARUNA THERAPEUTICS INC–0.6%$25.9m204,570–new
RVMD REVOLUTION MEDICINES INCHealthcare0.6%$25.8m1.32m–new
ARKG ARK ETF TR–0.5%$23.6m750,000–new
VIR VIR BIOTECHNOLOGY INCHealthcare0.4%$19.3m758,211−2.8%reduced
NKTX NKARTA INCHealthcare0.4%$17.4m1.41m–new
PHAT PHATHOM PHARMACEUTICALS INCHealthcare0.4%$16.2m1.92m−1.3%reduced
CRBU CARIBOU BIOSCIENCES INCHealthcare0.4%$16.0m2.95m+4.6%added
DCPHEUR DECIPHERA PHARMACEUTICALS IN–0.4%$15.8m1.20m–new
NUVB NUVATION BIO INCHealthcare0.4%$15.7m4.86m0.0%held
IOVA IOVANCE BIOTHERAPEUTICS INCHealthcare0.4%$15.4m1.39m−77%reduced
XENE XENON PHARMACEUTICALS INCHealthcare0.3%$13.7m450,000–new
SIBN SI-BONE INCHealthcare0.3%$13.2m1.00m0.0%held
SPNEUSD SEASPINE HLDGS CORP–0.3%$11.4m2.01m0.0%held
ATEC ALPHATEC HLDGS INCHealthcare0.3%$11.2m1.72m−37%reduced
APLSUSD APELLIS PHARMACEUTICALS INC–0.2%$9.7m215,000+2.4%added

Exited since Q1 2022

19 rows
MRK MERCK & CO. INC4.3%$194m
BAX BAXTER INTL INC3.3%$149m
BIOHAVEN PHARMACTL HLDG CO L no ticker3.2%$146m
MRTXEUR MIRATI THERAPEUTICS INC2.5%$115m
ISRG INTUITIVE SURGICAL INC2.2%$98.0m
ACET ADICET BIO INC1.4%$62.3m
EW EDWARDS LIFESCIENCES CORP1.1%$51.8m
BHC BAUSCH HEALTH COS INC0.9%$38.7m
INSM INSMED INC0.7%$31.8m
CCXIEUR CHEMOCENTRYX INC0.7%$29.5m
AXSM AXSOME THERAPEUTICS INC.0.7%$29.4m
RCUS ARCUS BIOSCIENCES INC0.6%$28.8m
PEN PENUMBRA INC0.5%$23.1m
VRDN VIRIDIAN THERAPEUTICS INC0.4%$19.2m
2655787D BLUEPRINT MEDICINES CORP0.4%$18.6m
LKFT LAKEFRONT BIOTHERAPEUTICS NV0.3%$13.3m
DYNAMICS SPECIAL PURPOSE COR no ticker0.1%$4.9m
HELIX ACQUISITION CORP no ticker0.10%$4.4m
2JQ GRITSTONE BIO INC0.05%$2.3m

Sector mix

  • Healthcare81.6%
  • Unclassified18.3%
  • Technology0.1%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters